
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion is well-positioned for growth due to its strong product portfolio and global presence, with a focus on aortic solutions for cardiac and vascular surgeons. While the company's non-North American revenue and tissue preservation services do present some risks, these are largely outweighed by the potential for growth through new product launches and international expansion. Despite temporary challenges that led to a recent guidance reduction, we believe Artivion's shares are undervalued compared to its peers, making it a positive investment opportunity.
Bears say
Artivion is facing challenges with their existing product, AMDS, due to HDE and IRB approval limitations and financial hurdles. While they have a strong pipeline and upcoming product launches, it is uncertain how successful these endeavors will be as they also face competition in the market. Additionally, new account onboarding has been hindered by the financial commitment required for their starter set, but management believes solutions are in place to address this issue.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares